Founded | 1989 (as Genetic Interest Group) |
---|---|
Type | Charitable organisation |
Registration no. | 1114195 |
Location |
|
Area served | United Kingdom |
Key people | Nick Meade and Lauren Roberts (Joint Interim Chief Executives), Elizabeth Porterfield (Chair) |
Website | www |
Genetic Alliance UK is a national charity and an alliance of over 200 patient organisations, supporting those affected by genetic conditions. [1] Genetic Alliance UK's aim is to improve the lives of people affected by genetic conditions, ensuring that high quality services and information are available to all who need them.
The group's work is primarily policy campaigns. It has campaigned for improved regulation and governance of clinical research, including animal research, improved access to new technology such as preimplantation genetic diagnosis, and has responded to Government consultations on the restructuring of the National Health Service between 2010 and 2012 to ensure that the needs of those with genetic conditions are properly addressed.
The group also commissions projects covering issues of common interest to its members; these have included insurance, prenatal diagnosis, patient access and patient information. It also works on gathering evidence of need through research projects and on directly improving information and services to patients.
The work has expanded outside the United Kingdom into the European Union. The group works through EGAN (European Genetic Alliance Network) to promote the interests of those with genetic conditions at European Commission and European Parliament.
1989: The group was founded in 1989 as Genetic Interest Group, after a group of approximately twelve charities proposed an alliance, with the backing of the British Clinical Genetics Society. [2]
1993: Genetic Interest Group became a founding member of the European Alliance of Genetic Support Groups (EAGS) – now known as the Patients’ Network for Health and Medical Research (EGAN).
1995: The Disability Discrimination Act passed. Genetic Interest Group lobbied to amend the Bill to ensure people pre-symptomatic for a genetic disorder would be protected against discrimination.
2003: Genetic Interest Group lobbied the Department of Health for more investment in rare disease research. There was a successful outcome in the White Paper on genetics on 24 June 2003, with £3 million earmarked to fund research into rare diseases.
2008: The Human Fertilisation and Embryology Act 2008 passed. Genetic Alliance UK's lobbying work influenced the law on a number of issues including preimplantation genetic testing, saviour siblings and human-animal hybrid embryos. Rare Disease UK was launched to campaign for a strategic approach to rare diseases in the UK.
2010: Genetic Interest Group became Genetic Alliance UK [3] - the decision was made to change the name and branding of the organisation to better reflect its work.
2011: SWAN UK (syndromes without a name) was relaunched as a project of Genetic Alliance UK, to continue supporting families of children with a syndrome without a name – taking over from Liz Swingwood, the grandmother of a child with an undiagnosed genetic condition.
2013: The UK Strategy for Rare Diseases was launched in November following years of hard work by our Rare Disease UK campaign.
2014: Genetic Alliance UK published its first patient charter, on the NICE Highly Specialised Technology Programme. Five patient charters on access to medicines and on genome sequencing have now been published.
The group now represents over 200 voluntary organisations and has representation on numerous bodies in the UK, Europe and the rest of the world.
2020: Genetic Alliance UK, through their campaign Rare Disease UK, held the first ever rare disease film festival [4] in the UK to both showcase and broaden the reach of rare disease focused film projects. Big winners on the night were Carl Mason and John Lee Taggart of charity Niemann-Pick UK (NPUK) for their film Go Make Memories, [5] which won both Best Picture and Best Charity Film. [6]
Rare Disease UK (RDUK) is a joint initiative of Genetic Alliance UK with other interested bodies. It focuses on the unmet healthcare needs of families with inadequate access to integrated care and support from the National Health Service. [7] It aims to ensure the efficient use of scarce expertise, and promote the targeted use of health care resources to maximise benefits for all patients and families affected by rare diseases in the UK.
Its programme advocates a coherent UK national strategy consisting of:
Rare Disease UK is the national campaign for people with rare diseases and all who support them. Rare Disease UK provides a united voice for the rare disease community by capturing the experiences of patients and families, working with supporters to raise the profile of rare diseases across the UK. Rare Disease UK seek to bring about lasting change offering better health and quality of life for individuals and families affected by rare diseases. Rare Disease UK is working with health departments across the UK to implement the UK Strategy for Rare Diseases to ensure that patients and families living with rare conditions have equitable access to high quality services, treatment and support. Rare Disease UK is a campaign run by Genetic Alliance UK, the national charity of over 200 patient organisations, supporting all those affected by genetic conditions.
SWAN UK (syndrome without a name) [8] is the only dedicated support network available for families of children and young adults (0–25 years) with undiagnosed genetic conditions in the UK. SWAN UK is free to join and has been run by the charity Genetic Alliance UK since 2011.
In 2015, SWAN UK created an animation called ‘Ellie's story' explaining what it means to have an undiagnosed genetic condition and how SWAN UK helps, supported by House of Fraser. [9]
A genetic disorder is a health problem caused by one or more abnormalities in the genome. It can be caused by a mutation in a single gene (monogenic) or multiple genes (polygenic) or by a chromosomal abnormality. Although polygenic disorders are the most common, the term is mostly used when discussing disorders with a single genetic cause, either in a gene or chromosome. The mutation responsible can occur spontaneously before embryonic development, or it can be inherited from two parents who are carriers of a faulty gene or from a parent with the disorder. When the genetic disorder is inherited from one or both parents, it is also classified as a hereditary disease. Some disorders are caused by a mutation on the X chromosome and have X-linked inheritance. Very few disorders are inherited on the Y chromosome or mitochondrial DNA.
A rare disease is a disease that affects a small percentage of the population. In some parts of the world, the term orphan disease describes a rare disease whose rarity results in little or no funding or research for treatments, without financial incentives from governments or other agencies. Orphan drugs are medications targeting orphan diseases.
Genetic counseling is the process of investigating individuals and families affected by or at risk of genetic disorders to help them understand and adapt to the medical, psychological and familial implications of genetic contributions to disease. This field is considered necessary for the implementation of genomic medicine. The process integrates:
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is one of the institutes and centers that make up the National Institutes of Health, an agency of the United States Department of Health and Human Services (HHS).
An idiopathic disease is any disease with an unknown cause or mechanism of apparent spontaneous origin. From Greek ἴδιος idios "one's own" and πάθος pathos "suffering", idiopathy means approximately "a disease of its own kind". For some medical conditions, one or more causes are somewhat understood, but in a certain percentage of people with the condition, the cause may not be readily apparent or characterized. In these cases, the origin of the condition is said to be idiopathic. With some other medical conditions, the root cause for a large percentage of all cases has not been established—for example, focal segmental glomerulosclerosis or ankylosing spondylitis; the majority of these cases are deemed idiopathic. Certain medical conditions, when idiopathic, notably some forms of epilepsy and stroke, are preferentially described by the synonymous term of cryptogenic.
Preimplantation genetic diagnosis is the genetic profiling of embryos prior to implantation, and sometimes even of oocytes prior to fertilization. PGD is considered in a similar fashion to prenatal diagnosis. When used to screen for a specific genetic disease, its main advantage is that it avoids selective abortion, as the method makes it highly likely that the baby will be free of the disease under consideration. PGD thus is an adjunct to assisted reproductive technology, and requires in vitro fertilization (IVF) to obtain oocytes or embryos for evaluation. Embryos are generally obtained through blastomere or blastocyst biopsy. The latter technique has proved to be less deleterious for the embryo, therefore it is advisable to perform the biopsy around day 5 or 6 of development.
Signs and symptoms are the observed or detectable signs, and experienced symptoms of an illness, injury, or condition.
Norrie disease is a rare disease and genetic disorder that primarily affects the eyes and almost always leads to blindness. It is caused by mutations in the Norrin cystine knot growth factor (NDP) gene, which is located on the X chromosome. In addition to the congenital ocular symptoms, the majority of patients experience a progressive hearing loss starting mostly in their 2nd decade of life, and some may have learning difficulties among other additional characteristics.
Medical genetics is the branch of medicine that involves the diagnosis and management of hereditary disorders. Medical genetics differs from human genetics in that human genetics is a field of scientific research that may or may not apply to medicine, while medical genetics refers to the application of genetics to medical care. For example, research on the causes and inheritance of genetic disorders would be considered within both human genetics and medical genetics, while the diagnosis, management, and counselling people with genetic disorders would be considered part of medical genetics.
Reproductive medicine is a branch of medicine concerning the male and female reproductive systems. It encompasses a variety of reproductive conditions, their prevention and assessment, as well as their subsequent treatment and prognosis.
The genetics and abortion issue is an extension of the abortion debate and the disability rights movement. Since the advent of forms of prenatal diagnosis, such as amniocentesis and ultrasound, it has become possible to detect the presence of congenital disorders in the fetus before birth. Specifically, disability-selective abortion is the abortion of fetuses that are found to have non-fatal mental or physical defects detected through prenatal testing. Many prenatal tests are now considered routine, such as testing for Down syndrome. Women who are discovered to be carrying fetuses with disabilities are often faced with the decision of whether to abort or to prepare to parent a child with disabilities.
Disorders of sex development (DSDs), also known as differences in sex development, diverse sex development and variations in sex characteristics (VSC), are congenital conditions affecting the reproductive system, in which development of chromosomal, gonadal, or anatomical sex is atypical.
Orphanet is an organisation and knowledge base dedicated to rare diseases as well as corresponding diagnosis, orphan drugs, clinical trials and expert networks.
The Royal Osteoporosis Society (ROS), formerly the National Osteoporosis Society, established in 1986, is the only UK-wide charity dedicated to improving the prevention, diagnosis and treatment of osteoporosis. It is based in Camerton, Somerset, England.
The National Prion Clinic (UK) is part of the University College London Hospitals NHS Foundation Trust. Its aim is to diagnose and treat patients with any form of human prion disease (Creutzfeldt-Jakob disease, CJD). In addition, the clinic facilitates research in diagnostics and therapeutics, organises clinical trials, and counsels those with an increased genetic risk of the disease.
The Huntington's Disease Association (HDA) is a charity that supports people in England and Wales affected by the genetic neurodegenerative brain condition Huntington's disease (HD).
Intersex people are born with natural variations in physical and sex characteristics including those of the chromosomes, gonads, sex hormones, or genitals that, according to the UN Office of the High Commissioner for Human Rights, "do not fit the typical definitions for male or female bodies". Such variations may involve genital ambiguity, and combinations of chromosomal genotype and sexual phenotype other than XY-male and XX-female. Preimplantation genetic diagnosis allows the elimination of embryos and fetuses with intersex traits and thus has an impact on discrimination against intersex people.
Maria Bitner-Glindzicz was a British medical doctor, honorary consultant in clinical genetics at Great Ormond Street Hospital, and a professor of human and molecular genetics at the UCL Institute of Child Health. The hospital described her work as relating to the "genetic causes of deafness in children and therapies that she hoped would one day restore vision." She researched Norrie disease and Usher syndrome, working with charities including Sparks and the Norrie Disease Foundation, and was one of the first colleagues involved in the 100,000 Genomes Project at Genomics England.
Dopamine transporter deficiency syndrome (DTDS), also known as infantile parkinsonism-dystonia, is a rare movement disorder that causes progressively worsening dystonia and parkinsonism. It is the first known inherited dopamine 'transportophathy.'